C. Galluzzo

Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study

C. Giaquinto, R. Badolato, F. Parazzini, 2018, The Journal of antimicrobial chemotherapy.

A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease.

D. Francisci, C. Tomino, S. Vella, 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

HIV-1 coreceptor switch during 2 years of structured treatment interruptions

L. Palmisano, M. Giuliano, S. Vella, 2013, European Journal of Clinical Microbiology and Infectious Diseases.

HIV‐related morbidity and mortality in patients starting protease inhibitors in very advanced HIV disease (CD4 count of < 50 cells/µL): an analysis of 338 clinical events from a randomized clinical trial *

C. Tomino, V. Fragola, M. Floridia, 2002, HIV medicine.

CD4/CD8 ratio in pregnant women with HIV and its association with pregnancy outcome: data from a national study in Italy

C. Giaquinto, R. Badolato, F. Parazzini, 2021, Infection.

A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection.

M. Moroni, L. Contu, A. Lazzarin, 2000, AIDS research and human retroviruses.

HIV-1 coreceptor switch during 2 years of structured treatment interruptions

L. Palmisano, M. Giuliano, S. Vella, 2013, European Journal of Clinical Microbiology & Infectious Diseases.

Risk factors and occurrence of rash in HIV‐positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside‐experienced patients with very low CD4 levels (<50 cells/mμL)

C. Tomino, S. Vella, R. Bucciardini, 2004, HIV medicine.